Are Allergy Drops FDA Approved? The Off-Label Explainer

No. Off-label use is legal and common throughout medicine; many widely used treatments are prescribed off-label based on clinical evidence and professional judgment. Not being FDA-approved means the specific compounded product did not go through the FDA's formal approval process, not that it is illegal or inherently dangerous. Sublingual immunotherapy generally has a favorable safety profile, with most side effects being mild and local, such as mouth itching. That said, off-label status is a real distinction patients should understand: there isn't an FDA-reviewed label defining the product, and insurers generally don't cover the drops for this reason. A prescriber still evaluates your case, screens for contraindications, and oversees treatment, which is an important safeguard regardless of approval status.

FDA-approved SLIT tablets—Grastek, Oralair, Ragwitek and Odactra—are standardized products for labelled allergens or allergen groups. Oralair contains five grass pollens. Personalized drops are compounded liquids prescribed off-label and may combine multiple allergens. Tablet approval does not extend to drops, and tablet trial results are not automatically evidence for a personalized formula. Tablets may be insured; compounded drops generally are not. Check the actual prescription, indication and benefits rather than assuming the two products are interchangeable.

No personalized compounded liquid SLIT product has FDA approval. FDA approval concerns a specific product and labelled route, dose and indication; the agency does not review compounded products before marketing. Do not infer that personalization alone explains nonapproval or proves safety and effectiveness. U.S. clinicians prescribe aqueous SLIT off-label using their assessment of the evidence and the individual patient, which is different from approval of the finished product.

Generally, no. Because custom liquid allergy drops are used off-label and are not an FDA-approved product, private insurers, Medicare, and Medicaid typically do not cover the drops themselves. There is no approved product code to reimburse. In some cases, a billable clinical or visit component may be partially covered, but the compounded drops are usually an out-of-pocket cost. The good news is that allergy drops are commonly HSA- and FSA-eligible, so you may be able to pay with pre-tax dollars. FDA-approved SLIT tablets, being standard prescription drugs, are more likely to be covered. If coverage matters to you, it is worth confirming the specifics with both your insurer and the program before starting.

No. SLIT has a substantial research base: the 2013 JAMA review found moderate-grade evidence for selected allergic-rhinitis outcomes, and the AAO-HNSF 2024 inhalant guideline includes discussion of aqueous SLIT. However, evidence varies by allergen and product. It does not establish that every compounded multi-allergen formula matches approved tablets or SCIT, and inhalant-allergy results cannot be used to claim food-allergy efficacy. FDA status and clinical evidence answer different questions; patients deserve both distinctions.

Watch for any language stating or implying that custom allergy drops are FDA-approved, FDA-cleared, or government-endorsed, because that is inaccurate; drops are used off-label. A common subtle tactic is to mention that sublingual immunotherapy or that SLIT tablets are FDA-approved and let the reader assume that approval extends to the company's liquid drops, which it does not. Accurate sources state plainly that custom drops are not FDA-approved and are used off-label, and they distinguish drops from the approved tablets, Grastek, Oralair, Ragwitek, and Odactra, by name. They also avoid cure or guarantee language. If a page leans on approval-sounding phrasing without that clear disclosure, treat it as a red flag and look for the off-label statement before trusting its other claims.

Yes, for inhalant allergy. The AAO-HNSF guideline's KAS 4 recommends educating candidates about SCIT and both aqueous and tablet SLIT, including risks, benefits, convenience and costs. Its Table 7 explicitly identifies aqueous SLIT as not FDA-approved in the U.S. It covers people aged 5 and older with allergic rhinitis, with or without allergic asthma; it is not evidence of food-allergy efficacy or approval of every compounded formula.